Our multi-antigen targeted T cells are designed to recognize and kill highly heterogeneous multiple tumor targets without the need for genetic modifications. Because our therapy does not require lymphodepletion or preconditioning for patients, our therapy has been shown to consistently induce epitope spreading to the patient’s own immune system. In clinical studies, our MultiTAA product candidates have been shown to be safe, contributing to durable anti-tumor responses.
Our therapy has been used to treat over 150 patients in seven different clinical trials by our collaborators at the Baylor College of Medicine in both blood malignancies and solid tumors. Based on these positive results of MultiTAA product candidates, we are advancing our first company-sponsored study in post-transplant acute myeloid leukemia in a potentially pivotal Phase 2 study.